

Specific issues from RAC and SEAC

Workshop on Streamlining Applications
for Authorisation


17 November 2015

Tim Bowmer

European Chemicals Agency, Helsinki

Outline

- Summary of RAC experience
- Summary of SEAC experience
- “Fit-for-purpose” applications



Summary of RAC experience




- Essential safety information in CSR **should not** be claimed as confidential – hinders evaluation
- Deviations from RAC Reference DNEs or dose-response curves have not generally been well justified
- Information on the hazard and especially the risk of alternatives often only poorly developed

Hierarchy of Controls

Most effective



Least effective



Elimination

Physically remove the hazard

Substitution

Replace the hazard

Engineering Controls

Isolate people from the hazard

Administrative Controls

Change the way people work

PPE

Protect the worker with Personal Protective Equipment

Source

Path

Worker

It is critical that RAC understands the process(es) and the respective RMM's

- Include descriptions, diagrams, photographs & videos– do not assume prior knowledge
- Address all relevant exposures e.g. inhalation, dermal, exposure via environment
- Describe the frequency, duration and overall sequence of activities / tasks
- Who performs each of the tasks – is there potential for shift-long, combined, exposure?
- Identify and clarify situations where the usual RMMs may not work (e.g. maintenance, cleaning, sampling, laboratory ...)

Operating Conditions & Risk Management Measures 1

Engineering controls

- Use of closed (and automated) systems:
 - Often claimed - but not always substantiated based on monitoring. May still need to be combined with other RMMs to ensure control of exposure (e.g. types of ventilation, enclosure)
 - Do manual tasks still occur with potential for exposure?
- General and Local Exhaust Ventilation (LEV): is not always sufficiently described (e.g. location, effectiveness, maintenance, exhaust treatment)

Operating Conditions & Risk Management Measures 2

- **Administrative and organisation controls**
 - Training, maintenance, supervision, access restriction, hygiene
- **Use of Personal Protective Equipment (PPE)**
 - Justification for the selection of specific PPE not always provided – filter type / glove type
 - Over-reliance on high-efficiency PPE equipment (is it feasible to work in for long stretches and effective?)
 - Is PPE properly maintained and replaced as necessary?

- Exposure measurements preferred
 - often sparse – contextual information is often missing or incomplete
 - LOD/LOQ, number of samples, duration of sampling, task performed during sampling, static or personal, uncertainty (mean vs 90th percentile)
- Exposure modelling - useful and could have improved several cases considerably
 - Often reported insufficiently (input parameters missing / incomplete)
 - Overreliance on Tier I (screening) models
- Biomonitoring useful where an appropriate method is available
- Express exposure and risk with and without PPE
 - if only with PPE, then specify and document the efficiency of the equipment



Identify and clarify situations where the usual RMMs may not work (e.g. sampling, maintenance, cleaning, laboratory ...)

Summary of SEAC experience



General

- Applicants are increasingly focusing on the business reasons for applying in their AoAs and SEAs
 - When the key business drivers are clear to SEAC, this facilitates the evaluation
- Most applicants have used the RAC reference values
 - Simplified the applicants' work and facilitates SEAC when evaluating the health impact assessment and valuation
- Many have carried out a full cost-benefit analysis and provided the spreadsheets
 - Helped SEAC to evaluate and draw conclusions for their opinion
- There are still transparency issues around data sources, assumptions and methodology, particularly in relation to the assessment of costs in the non-use scenario
 - SEAC should be able to trace data and reproduce the results

Analysis of alternatives (AoA)

- The analysis of the existing alternatives should be based on the applicant's context, in terms of technologies, markets etc.
- Identification of alternative substances and technologies
 - Some applicants have not explained
 - how the short-list of alternatives was derived
 - if the function of Annex XIV substance could be replaced
 - why some "sub-uses" could be substituted while others not
- Assessment of alternatives
 - Time and resources to transition to an alternative not sufficiently well justified
 - Commercially available alternatives sometimes not included in the analysis
- AoAs were not always used as the basis for defining the non-use scenario in the SEA

Socio-economic Analysis (SEA)

- The non-use scenario did not always seem credible
 - “Shut-down” or “complete relocation” not analytically supportable
 - Include a discussion of the applicant’s options – what would be the impacts of changing to an alternative?
- Some applicants have not focused on net costs
 - If an operation is closed down, there will be “savings” as well
 - An alternative could be more expensive but result in some gains (e.g. in energy consumption or quality)
 - Double counting of costs along the supply chain should also be avoided
- Some applicants have estimated the cost of unemployment based on lost salaries
 - But the freed up labour cost can be spent on other economic activities. For the truly involuntary unemployed, social cost is less than wage
- Some applicants have estimated the loss of revenues
 - This would inflate the losses (as the expenditure would go down too). Loss of e.g. net margin or net operational profit would be a more accurate comparator.

Concluding on impacts

- Impacts were not always analysed from society's perspective
 - The use of a substance might be critical to one company, but its suppliers, customers or competitors might easily do without it
 - Lost revenue of someone in the supply chain may be compensated by increased revenue of those supplying or using the alternatives
- Assumptions and uncertainties not always recognised
 - Uncertainty does not in itself invalidate the conclusions but they need to be described and, where possible, minimised
 - An uncertainty analysis tests whether different assumptions or estimates could affect the conclusions and, if so, how significant this effect may be.
- Many applicants have justified their review period requests
 - SEAC looks at every application with the "review process" firmly in mind
 - Linked to availability of alternatives and timeline for substitution
 - Recommend a short review period where there are significant uncertainties in CSR, AoA or SEA

“Fit-for-purpose” applications



How the committees derive review periods

- RAC assesses the risks and the uncertainties of the CSR. To a large extent, RAC's message to SEAC is concerned with the uncertainties
- SEAC accounts for the uncertainties highlighted by RAC and those from the SEA and AoA in their opinion, mainly in the recommendation on the length of the review period.
- The normal review period is 7 years
- Large uncertainties in the RAC and/or SEAC evaluation lead to a shorter review period. Too large uncertainties could result in rejection or non-evaluation.
- Less uncertainty combined with a clear motivation can lead to a long review period

What might be considered a “fit-for-purpose” analysis?

- Balanced and fact-based – conclusions are well justified
- Focuses on the factors that are likely to make a difference
- Not overly complicated, especially when the risk/benefit ratio is high and robust
- Uncertainties are recognised, described and their consequences are analysed
- Sufficient information is provided to reproduce estimations and calculations

- Provide clear descriptions and illustrate the process and the worker activities covered in the exposure scenarios
- Describe all RMM in place to control/minimise exposure
 - OC, RMM: engineering, administrative and PPE, effectiveness where appropriate
- RAC has a strong preference for measured data
 - Supplement limited measured data with modelled values - try and corroborate
 - Include contextual information alongside monitoring data and all input parameters for modelling

Fit-for-purpose in SEAC

- Descriptions of technical functions in AoA should be concise and meaningful for non-experts
- Briefly describe any shortlisting criteria and process
 - No need to list thousands of substances
 - Equally or more hazardous alternatives in general should not be shortlisted
 - Include alternative substances and technologies used by competitors
- A comprehensive risk assessment of an alternative is not needed except where the alternative is technically and economically feasible (but riskier)
- The economic feasibility assessment can be based on typical costs within a sector. Detailed specifications for new plants are not required.
- Describe your substitution efforts to substantiate the requested review period

Fit-for-purpose in SEAC

- The analysis of alternatives should be the basis for developing non-use scenarios but adopting an alternative does not need to be the most likely non-use scenario
 - The joint AoA/SEA format supports the link between the two reports
- Justify the selection of the most likely non-use scenario and focus the analysis of socio-economic impacts on that
 - The key arguments should be clear without lengthy text
 - Calculations should be clear to SEAC, e.g. by providing spreadsheets
- Focus on demonstrating that the benefits of continued use outweigh the risks
 - The lower and more certain the health and environmental impacts of continued use are, the less effort is required when estimating costs

Making a recommendation on an application...

Adequate control route (threshold substances)

- *The risk to human health or the environment from the use of a substance arising from the intrinsic properties specified in Annex XIV is adequately controlled (RCR<1)*

Socio-economic route (non-threshold substances or adequate control not supported)

- *The socio-economic benefits outweigh the risks to human health or the environment, and*
- *no suitable alternative substances or technologies are available*

RAC formulates its recommendation on the basis of:

- The risks posed by the use (and the alternatives), including the hazard and exposure assessment
- Appropriateness and effectiveness of risk management measures (RMM) in place
- Achieving adequate control or minimisation

RAC may recommend:

- Additional conditions
 - Related to continued use of the substance e.g. review and/or improvement of RMMs
 - Related to the review report, e.g. monitoring

RAC communicates its concerns regarding the risks and the uncertainties to SEAC

SEAC evaluates and formulates its recommendation on the basis of:

- Whether the socio-economic benefits of authorisation outweigh the risks of continued use (when the risks are not adequately controlled)
- The technical and economic feasibility and availability of alternatives
- The length of the time-limited review period requested by the applicant

Outcomes: in a worst case

- RAC and/or SEAC may not be able to evaluate an application
 - Has already occurred
- RAC may decide that there is no adequate control
 - SEA route follows and exposure minimisation
 - Has already occurred
- SEAC may not support the granting of an application for authorisation
 - Not yet the case, but some applications have had recommendations for shorter review periods than 4 years

Fit-for-purpose in RAC: Upstream/umbrella applications

- May cover one large business or multiple unconnected businesses
- Usually cover multiple sites and workplaces
- One use may cover wide variations on the same process in terms of scale (size, workforce and geography), technology and RMMs
- Difficult to evaluate without representative exposure scenarios
- Representative data is needed to cover the scale, process technology and the diverse RMMs in place
- Explain how the data provided adequately represents the expected variability in exposure
- In short, address the uncertainties adequately

Thank you

Subscribe to our news at echa.europa.eu/subscribe

Follow us on Twitter
[@EU_ECHA](https://twitter.com/EU_ECHA)

Follow us on Facebook
Facebook.com/EUECHA